tbuckley/cabot-search huggingface dataset:
Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study
Authors: Balazs Acs, Johan Hartman, Demet Sönmez, Henrik Lindman, Anna L.V. Johansson, Irma Fredriksson
Journal: The Lancet Regional Health - Europe (2024)

BackgroundEstrogen receptor-low (ER-low) HER2-negative breast cancer has similar pathological and molecular characteristics as triple-negative breast cancer (TNBC), and it is questionable whether it should be considered a separate entity. When the international guidelines lowered the cutoff for ER positivity to ≥1% in 2010, the ≥10% threshold was kept in Sweden. ER-low breast cancer (ER 1–9%) is thus in Sweden treated as TNBC. We aimed to describe patient and tumor characteristics, treatment patterns and overall survival in a Swedish population-based cohort of patients with ER-zero and ER-low HER2-negative breast cancer treated as TNBC.MethodsAll TNBC cases diagnosed in Sweden 2008–2020 were included in a population-based cohort study. Patient, tumor and treatment characteristics were analyzed by ER-status (ER 0% vs 1–9%), and associations between subgroups compared using χ2 test. Survival endpoint was overall survival (OS), and Kaplan–Meier curves were estimated. Cox proportional hazards models were used to estimate adjusted hazard ratios comparing ER-low to ER-zero.FindingsOf the 5655 tumors, 90.1% had an ER expression of 0%, while 9.9% were ER-low. ER-low tumors were grade III in 69.4% (80.8% in ER-zero tumors, p-value = 0.001), with a median Ki67 of 60% (63% in ER-zero tumors, p-value = 0.005). There were no significant differences in given chemotherapy (p = 0.546). A pathological complete response (pCR) was achieved in 28.1% of ER-low tumors (25.1% in ER-zero tumors). In the unadjusted analysis of OS, women with ER-low disease had a borderline but not significantly better OS than those with ER-zero disease (HR 0.84 (95% CI 0.71–1.00), p = 0.052). ER-status 1–9% vs 0% was not associated with OS in the multivariable analysis (HR 1.11 (0.90–1.36)). Distant disease-free survival did not differ by ER-status 0% vs 1–9% (HR 0.97 for ER-zero vs ER-low (0.62–1.53), p = 0.905). After preoperative treatment, the impact of pCR for OS did not significantly differ between ER-zero or ER-low disease.InterpretationER-low HER2-negative breast cancer has characteristics and prognosis similar to TNBC, when treated in the same way. Therefore, it seems reasonable to use a ≥10% threshold for ER positivity. This would provide patients with ER-low tumors the same treatment opportunities as patients with TNBC, within studies and within clinical routine.FundingThis work was financially supported by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, in accordance with terms and conditions of a Master Collaboration Agreement between the company and Karolinska Institutet.
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Authors: Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill, Vasilios Kotsis, Rohit Loomba, Arun J. Sanyal, Christos S. Mantzoros
Journal: Metabolism (2024)
Bacteriome and mycobiome dysbiosis in oral mucosal dysplasia and oral cancer
Authors: Georgios N. Belibasakis, Chaminda Jayampath Seneviratne, Ruwan Duminda Jayasinghe, Phuc Thi‐Duy Vo, Nagihan Bostanci, Youngnim Choi
Journal: Periodontology 2000 (2024)

Abstract It has long been considered that the oral microbiome is tightly connected to oral health and that dysbiotic changes can be detrimental to the occurrence and progression of dysplastic oral mucosal lesions or oral cancer. Improved understanding of the concepts of microbial dysbiosis together with advances in high‐throughput molecular sequencing of these pathologies have charted in greater microbiological detail the nature of their clinical state. This review discusses the bacteriome and mycobiome associated with oral mucosal lesions, oral candidiasis, and oral squamous cell carcinoma, aiming to delineate the information available to date in pursuit of advancing diagnostic and prognostic utilities for oral medicine.
Oncogenic KRAS induces arginine auxotrophy and confers a therapeutic vulnerability to SLC7A1 inhibition in non-small cell lung cancer
Authors: Xiameng Gai, Yingluo Liu, Xiaojing Lan, Luoyi Chen, Tao Yuan, Jun Xu, Yize Li, Ying Zheng, Yiyang Yan, Liya Yang, Yixian Fu, Shuai Tang, Siyuwei Cao, Xiaoyang Dai, Hong Zhu, Meiyu Geng, Jian Ding, Congying Pu, Min Huang
Journal: Cancer Research (2024)

The urea cycle is frequently rewired in cancer cells to meet the metabolic demands of cancer. Elucidation of the underlying mechanism by which oncogenic signaling mediates urea cycle reprogramming could help identify targetable metabolic vulnerabilities. In this study, we discovered that oncogenic activation of KRAS in non-small cell lung cancer (NSCLC) silenced the expression of argininosuccinate synthase 1 (ASS1), a urea cycle enzyme that catalyzes the production of arginine from aspartate and citrulline, and thereby diverted the utilization of aspartate to pyrimidine synthesis to meet the high demand for DNA replication. Specifically, KRAS signaling facilitated a hypoacetylated state in the promoter region of the ASS1 gene in a histone deacetylase 3-dependent manner, which in turn impeded the recruitment of c-MYC for ASS1 transcription. ASS1 suppression in KRAS-mutant NSCLC cells impaired the biosynthesis of arginine and rendered a dependency on the arginine transmembrane transporter SLC7A1 to import extracellular arginine. Depletion of SLC7A1 in both patient-derived organoid and xenograft models inhibited KRAS-driven NSCLC growth. Together, these findings uncover the role of oncogenic KRAS in rewiring urea cycle metabolism and identify SLC7A1-mediated arginine uptake as a therapeutic vulnerability for treating KRAS-mutant NSCLC.
Tight versus liberal blood-glucose control in the intensive care unit: special considerations for patients with diabetes
Authors: Christian von Loeffelholz, Andreas L Birkenfeld
Journal: The Lancet Diabetes & Endocrinology (2024)

Stress hyperglycaemia, hypoglycaemia, and diabetes are common in critically ill patients and related to clinical endpoints. To avoid complications related to hypoglycaemia and hyperglycaemia, it is recommended to start insulin therapy for the majority of critically ill patients with persistent blood glucose concentrations higher than 10·0 mmol/L (>180 mg/dL), targeting a range of 7·8–10·0 mmol/L (140–180 mg/dL). However, management and evidence-based targets for blood glucose control are under debate, particularly for patients with diabetes. Recent randomised controlled clinical trials now challenge current recommendations. In this Personal View, we aim to highlight these developments and the important differences between critically ill patients with and without diabetes, taking into account the considerable heterogeneity in this patient group. We critically discuss evidence from prospective randomised controlled trials and observational studies on the safety and efficacy of glycaemic control, specifically in the context of patients with diabetes in intensive care units.
Persistent increase of cardiovascular and cerebrovascular events in COVID-19 patients: a 3-year population-based analysis
Authors: Allegra Battistoni, Massimo Volpe, Carmine Morisco, Gaetano Piccinocchi, Roberto Piccinocchi, Massimo Fini, Stefania Proietti, Stefano Bonassi, Bruno Trimarco
Journal: Cardiovascular Research (2024)

We evaluated the incidence and relative risk of major post-acute cardiovascular consequences of SARS-CoV-2 infection in a large real-world population from a primary care database in a region at moderate cardiovascular risk followed up in the period 2020-22.
Intracardiac Ultrasound and Mapping Integration-Guided Endomyocardial Biopsy for the Diagnosis of Myocardial Melanoma Metastasis
Authors: Jerry Fan, Christopher Perez, Robert J. Widmer, Vinh Nguyen, Gang Zhou, Laith Wahab, Javier E. Banchs
Journal: JACC CardioOncology (2024)
CRISPR-Cas9 Genome Editing Allows Generation of the Mouse Lung in a Rat
Authors: Bingqiang Wen, Enhong Li, Guolun Wang, Timothy R. Kalin, Dengfeng Gao, Peixin Lu, Tanya V. Kalin, Vladimir V. Kalinichenko
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Recent efforts in bioengineering and embryonic stem cell (ESC) technology allowed the generation of ESC-derived mouse lung tissues in transgenic mice that were missing critical morphogenetic genes. Epithelial cell lineages were efficiently generated from ESC, but other cell types were mosaic. A complete contribution of donor ESCs to lung tissue has never been achieved. The mouse lung has never been generated in a rat.
Orofacial Anomalies in Kindler Epidermolysis Bullosa
Authors: Susanne Krämer, Anna Lena Hillebrecht, Yao Wang, Mihail-Alexandru Badea, Jose Ignacio Barrios, Sorina Danescu, Ignacia Fuentes, Demet Kartal, Alfred Klausegger, Enrique Ponce de León, Reinhard Schilke, Ivelina Yordanova, Agnes Bloch-Zupan, Cristina Has
Journal: JAMA Dermatology (2024)

Importance Kindler epidermolysis bullosa is a genetic skin-blistering disease associated with recessive inherited pathogenic variants in FERMT1 , which encodes kindlin-1. Severe orofacial manifestations of Kindler epidermolysis bullosa, including early oral squamous cell carcinoma, have been reported. Objective To determine whether hypoplastic pitted amelogenesis imperfecta is a feature of Kindler epidermolysis bullosa. Design, Settings, and Participants This longitudinal, 2-center cohort study was performed from 2003 to 2023 at the Epidermolysis Bullosa Centre, University of Freiburg, Germany, and the Special Care Dentistry Clinic, University of Chile in association with DEBRA Chile. Participants included a convenience sampling of all patients with a diagnosis of Kindler epidermolysis bullosa. Main Outcomes and Measures The primary outcomes were the presence of hypoplastic pitted amelogenesis imperfecta, intraoral wounds, gingivitis and periodontal disease, gingival hyperplasia, vestibular obliteration, cheilitis, angular cheilitis, chronic lip wounds, microstomia, and oral squamous cell carcinoma. Results The cohort consisted of 36 patients (15 female [42%] and 21 male [58%]; mean age at first examination, 23 years [range, 2 weeks to 70 years]) with Kindler epidermolysis bullosa. The follow-up ranged from 1 to 24 years. The enamel structure was assessed in 11 patients, all of whom presented with enamel structure abnormalities. The severity of hypoplastic pitted amelogenesis imperfecta varied from generalized to localized pitting. Additional orofacial features observed include gingivitis and periodontal disease, which was present in 90% (27 of 30 patients) of those assessed, followed by intraoral lesions (16 of 22 patients [73%]), angular cheilitis (24 of 33 patients [73%]), cheilitis (22 of 34 patients [65%]), gingival overgrowth (17 of 26 patients [65%]), microstomia (14 of 25 patients [56%]), and vestibular obliteration (8 of 16 patients [50%]). Other features included chronic lip ulcers (2 patients) and oral squamous cell carcinoma with lethal outcome (2 patients). Conclusions and Relevance These findings suggest that hypoplastic pitted amelogenesis imperfecta is a feature of Kindler epidermolysis bullosa and underscore the extent and severity of oral manifestations in Kindler epidermolysis bullosa and the need for early and sustained dental care.
Considerations Regarding Mohs Surgery for Early-Stage Merkel Cell Carcinoma
Authors: Mark B. Faries
Journal: JAMA Dermatology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials
Authors: Sheila Shaigany, Nicole Mastacouris, Rachel Tannenbaum, Andrew Strunk, Christopher Luan, Joshua Burshtein, Aaron Burshtein, Richard Carvajal, Amit Garg, Allireza Alloo
Journal: JAMA Dermatology (2024)

Assessment of type, severity, and impact of dermatologic adverse events (DAEs) necessitates well-developed and validated clinician-reported outcome measures (ClinROMs) and patient-reported outcome measures (PROMs) that evaluate concepts specific to mucocutaneous toxic effects and that allow appropriate interpretation and comparison of DAEs across trials.
Reanalysis of Study After Removal of Participants in 1 Trial of Upadacitinib for Atopic Dermatitis
Authors: Amy S. Paller
Journal: JAMA Dermatology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Considerations Regarding Mohs Surgery for Early-Stage Merkel Cell Carcinoma—Reply
Authors: Shayan Cheraghlou, John A. Carucci
Journal: JAMA Dermatology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Improved Dermatologist, Patient, and Oncologist Collaboration Needed During Cancer Drug Development
Authors: Bernice Y. Kwong
Journal: JAMA Dermatology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Considerations Regarding Mohs Surgery for Early-Stage Merkel Cell Carcinoma
Authors: Suraj S. Venna, Peter H. Goff, Isaac Brownell
Journal: JAMA Dermatology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Early PPROM: women and babies who should not be lost in the system
Authors: Laura Goodfellow, Ciara Curran, Angharad Care
Journal: BMJ (2024)

There are no national or international agreements about how to manage women with early preterm prelabour rupture of membranes, and services are inadequately organised for their needs, write Laura Goodfellow, Ciara Curran, and Angharad Care
Interleukin-4 downregulates transcription factor BCL6 to promote memory B cell selection in germinal centers
Authors: Laila Shehata, Christopher D. Thouvenel, Brian D. Hondowicz, Lucia A. Pew, Gretchen Harms Pritchard, David J. Rawlings, Jinyong Choi, Marion Pepper
Journal: Immunity (2024)
Epithelial-derived interleukin-23 promotes oral mucosal immunopathology
Authors: Tae Sung Kim, Tomoko Ikeuchi, Vasileios Ionas Theofilou, Drake Winslow Williams, Teresa Greenwell-Wild, Armond June, Emmanuel E. Adade, Lu Li, Loreto Abusleme, Nicolas Dutzan, Yao Yuan, Laurie Brenchley, Nicolas Bouladoux, Yosuke Sakamachi, Robert J. Palmer, Ramiro Iglesias-Bartolome, Giorgio Trinchieri, Stavros Garantziotis, Yasmine Belkaid, Alex M. Valm, Patricia I. Diaz, Steven M. Holland, Niki M. Moutsopoulos
Journal: Immunity (2024)
Engineered hsa‐miR‐455‐3p‐Abundant Extracellular Vesicles Derived from 3D‐Cultured Adipose Mesenchymal Stem Cells for Tissue‐Engineering Hyaline Cartilage Regeneration
Authors: Jian‐Guo Chen, En‐Chong Zhang, Ying‐Ying Wan, Tian‐Yu Huang, Yu‐Chen Wang, Hai‐Yue Jiang
Journal: Advanced Healthcare Materials (2024)

Efforts are made to enhance the inherent potential of extracellular vesicles (EVs) by utilizing 3D culture platforms and engineered strategies for functional cargo-loading. Three distinct types of adipose mesenchymal stem cells-derived EVs (ADSCs-EVs) are successfully isolated utilizing 3D culture platforms consisting of porous gelatin methacryloyl (PG), PG combined with sericin methacryloyl (PG/SerMA), or PG combined with chondroitin sulfate methacryloyl (PG/ChSMA). These correspond to PG-EVs, PG/SerMA-EVs, and PG/ChSMA-EVs, respectively. Unique microRNA (miRNA) profiles are observed in each type of ADSCs-EVs. Notably, PG-EVs encapsulate higher levels of hsa-miR-455-3p and deliver more hsa-miR-455-3p to chondrocytes, which results in the activation of the hsa-miR-455-3p/PAK2/Smad2/3 axis and the subsequent hyaline cartilage regeneration. Furthermore, the functionality of PG-EVs is optimized through engineered strategies, including agomir/lentivirus transfection, electroporation, and Exo-Fect transfection. These strategies, referred to as Agomir-EVs, Lentivirus-EVs, Electroporation-EVs, and Exo-Fect-EVs, respectively, are ranked based on their efficacy in encapsulating hsa-miR-455-3p, delivering hsa-miR-455-3p to chondrocytes, and promoting cartilage formation via the hsa-miR-455-3p/PAK2/Smad2/3 axis. Notably, Exo-Fect-EVs exhibit the highest efficiency. Collectively, the 3D culture conditions and engineered strategies have an impact on the miRNA profiles and cartilage regeneration capabilities of ADSCs-EVs. The findings provide valuable insights into the mechanisms underlying the promotion of cartilage regeneration by ADSCs-EVs.
Engineering nanomedicines for immunogenic eradication of cancer cells: Recent trends and synergistic approaches
Authors: Ahmed O. Elzoghby, Omar Samir, Hagar E. Emam, Ahmed Soliman, Riham M. Abdelgalil, Yomna M. Elmorshedy, Kadria A. Elkhodairy, Mahmoud L. Nasr
Journal: Acta Pharmaceutica Sinica B (2024)

Resistance to cancer immunotherapy is mainly attributed to poor tumor immunogenicity as well as the immunosuppressive tumor microenvironment (TME) leading to failure of immune response. Numerous therapeutic strategies including chemotherapy, radiotherapy, photodynamic, photothermal, magnetic, chemodynamic, sonodynamic and oncolytic therapy, have been developed to induce immunogenic cell death (ICD) of cancer cells and thereby elicit immunogenicity and boost the antitumor immune response. However, many challenges hamper the clinical application of ICD inducers resulting in modest immunogenic response. Here, we outline the current state of using nanomedicines for boosting ICD of cancer cells. Moreover, synergistic approaches used in combination with ICD inducing nanomedicines for remodeling the TME
Utility and Validity of the HFA-PEFF and H2FPEF Scores in Patients With Symptomatic Atrial Fibrillation
Authors: Jonathan P. Ariyaratnam, Ricardo S. Mishima, Kadhim Kadhim, Mehrdad Emami, John L. Fitzgerald, Anand Thiyagarajah, Jenelle K. Dziano, Jackson O. Howie, Melissa E. Middeldorp, Prashanthan Sanders, Adrian D. Elliott
Journal: JACC Heart Failure (2024)
Nanoparticle drug delivery system for the treatment of brain tumors: Breaching the blood–brain barrier
Authors: Qiyu Tang, Guo Zhao, Hong Fang, Yale Jiang, Peiwen Ma, Jiawei Zhou, Dongyan Liu, Shujun Xing, Gaoquan Li, Nian Liu, Huiyu Chen, Shuhang Wang, Ning Li
Journal: Acta Pharmaceutica Sinica B (2024)

The current status of clinical trials utilizing nanoparticle drug delivery system (NDDS) for brain tumors was summarized.Image 1.